This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Coronary CT angiography for the suspected progression of known coronaryarterydisease in a 56-year-old female patient. mm (green outline) section thickness show the respective calcified plaque (arrowheads) and coronary stenosis (inset images). Curved multiplanar reconstructions with 0.6-mm
mtaschetta-millane Thu, 07/18/2024 - 10:00 July 18, 2024 — HeartFlow, Inc. , Having access to a patient’s whole coronary picture, with both quantified plaque and physiology, is a game changer as a clinician. Accurately diagnosing a patient’s risk for coronaryarterydisease is critical for determining the best treatment.
Cleerly, a digital healthcare company focused on heart disease, has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging. 25, 2024 in the European Heart Journal Cardiovascular Imaging 1.
tim.hodson Mon, 11/18/2024 - 10:55 Nov. Patient Demographics: Patients on APT had a higher rate of coronaryarterydisease (70% vs. 42%), previous heart attacks (36% vs. 16%), and peripheral arterydisease (15% vs. 11%). For more information, please visit anthostherapeutics.com.
mtaschetta-millane Thu, 07/25/2024 - 08:55 July 25, 2024 — Nanox, an innovative medical imaging technology company, announced that the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox.AI was highlighted in multiple scientific presentations at the 2024 Society of Cardiovascular Computed Tomography (SCCT) Annual Meeting. “We
In 2024, the FDA approved Flyrcado for patients with known or suspected coronaryarterydisease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. link] ii Miller, R.
Publication date: 15 January 2024 Source: The American Journal of Cardiology, Volume 211 Author(s): Namrita D. Ashokprabhu, Jessie Fox, Timothy D. Henry, Christian W. Schmidt, Darlene Tierney, Julie Gallatin, Yulith Roca Alvarez, Lauren Thompson, Michelle Hamstra, Sachin A. Shah, Odayme Quesada
New data reveal that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronaryarterydisease (CAD).
A rare variant association study using exome sequencing data was performed on a machine learning-based marker for coronaryarterydisease (CAD). Our findings help us understand how these 17 genes are involved in coronaryarterydisease. Credit: Ron Do, PhD, and Ben Omega Petrazzini, BS, at Icahn Mount Sinai.
More than half of the patients presented with heart failure (n=2,234, 55.4%), followed by acute myocardial infarction (n=1,368, 34.0%), coronaryarterydisease (n=674, 16.7%), and acute coronary syndrome (n=164, 4.1%). Poor ventricular function (26.16.8
milla1cf Tue, 01/23/2024 - 13:44 January 23, 2024 — HeartFlow, Inc. , a leader in non-invasive artificial intelligence (AI) precision coronary solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT) code beginning January 1, 2024.
DALLAS, JANUARY 16, 2024 — A patient’s oral health can be an indicator of overall health and well-being. Research shows that chronic gum inflammation may be associated with other chronic diseases including coronaryarterydisease and diabetes.[1]
Performing percutaneous coronary intervention (PCI) significantly improved outcomes in patients with stable coronaryarterydisease (CAD) and severe aortic stenosis selected for transcatheter aortic valve implantation (TAVI), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Circulation: Genomic and Precision Medicine, Volume 17, Issue 6 , Page e004674, December 1, 2024. BACKGROUND:Genome-wide association studies identified a 20-Kb region of chromosome 8 (8q24.13) associated with plasma lipids, hepatic steatosis, and risk for coronaryarterydisease. locus to these traits.
The National Institute for Health and Care Excellence (NICE) advise against routine testing for coronaryarterydisease (CAD) in patients with non-anginal chest pain (NACP). Over 23 months, 866 patients with NACP underwent CTCA.
Circulation, Volume 150, Issue Suppl_1 , Page A4140139-A4140139, November 12, 2024. Introduction:The cardio-ankle vascular index (CAVI) is a significant metric for evaluating arterial function. Recent statistics indicate that a high CAVI score has the potential to predict future cardiovascular disease (CVD) occurrences.
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
milla1cf Tue, 06/25/2024 - 18:58 June 25, 2024 — Nano-X Imaging (Nanox), an innovative medical imaging technology company, today announced that data from five studies supporting the AI Cardiac Solution (HealthCCSng) of its subsidiary, Nanox AI, will be presented at the 19th Annual Meeting of the Society of Cardiovascular Computed Tomography ( SCCT (..)
Background Percutaneous coronary intervention (PCI) is a well-established treatment for coronaryarterydisease, one of the most significant causes of morbidity and mortality worldwide. Costs were categorised as staffing, capital and consumables. Staffing costs were calculated in accordance with local guidelines.
milla1cf Fri, 02/23/2024 - 11:54 February 23, 2024 — Cleerly , the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Earls, MD , Chief Medical Officer of Cleerly. Bär S, Nabeta T, Maaniitty T. Eur Heart J Cardiovasc Imaging. 2023 Dec 12:jead339. PMID: 38084894.
milla1cf Tue, 01/09/2024 - 11:32 January 9, 2024 — Cleerly , the company working to create a new standard of care for the diagnosis of heart disease, announced the launch of Cleerly ISCHEMIA , which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance.
milla1cf Fri, 03/01/2024 - 08:50 March 1, 2024 — Boston Scientific Corporation today announced it has received U.S. Food and Drug Administration ( FDA ) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronaryarterydisease.
milla1cf Wed, 01/03/2024 - 11:45 January 3, 2024 — HeartFlow, Inc. , a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFR CT Analysis.
Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor (VEGF) gene therapy treatment for patients who have advanced coronaryarterydisease (CAD).
mtaschetta-millane Tue, 07/23/2024 - 10:59 July 23, 2024 — The Society of Cardiovascular Computed Tomography (SCCT) announced its best original science award winners of the 19th Annual Scientific Meeting (SCCT2024) in Washington, DC.
The optimal management of concomitant chronic obstructive coronaryarterydisease (CAD) in transcatheter aortic valve replacement (TAVR) recipients remains a debated topic. While some advocate for pre-TAVR percutaneous coronary intervention, others adopt an expectant approach. European Heart Journal 2024.
Nature Reviews Cardiology, Published online: 07 May 2024; doi:10.1038/s41569-024-01014-0 In 1993, Lincoff and Topol claimed that the thrombolytic treatment of ST-segment elevation myocardial infarction was suboptimal in many patients and gave an ‘illusion of reperfusion’.
Methods and results MEDLINE, Cochrane Library and Scopus were searched until 12 December 2024. To address these inconsistencies, the present meta-analysis aimed to evaluate the association of CH with the incidence and clinical outcomes of HF. Triple-independent study selection, data extraction and quality assessment were performed.
Objective We aimed to summarize the association between gestational diabetes mellitus (GDM) and its intergenerational cardiovascular diseases (CVDs) impacts in both mothers and offspring post-delivery in existing literature.
Getty Images milla1cf Mon, 06/10/2024 - 18:02 June 10, 2024 — New expert consensus from the Society of Cardiovascular Computed Tomography (SCCT) reviews previously published qualitative and semi-quantitative measurements – including clinical guidelines like CAD-RADS 2.0
milla1cf Thu, 03/28/2024 - 07:00 March 28, 2024 — Cleerly , the company on a mission to create a new standard of care to aid in the diagnosis of heart disease, shared findings from a study published online in the Journal of the American College of Cardiology: Cardiovascular Imaging on March 13, 2024. 2024.01.007.
Circulation, Volume 150, Issue Suppl_1 , Page A4136459-A4136459, November 12, 2024. Introduction:Patients with Type 2 diabetes mellitus (T2DM) have an increased risk for coronaryarterydisease (CAD) compared to patients without T2DM.
June 27, 2024 — The countdown has begun for the Society of Cardiovascular Computed Tomography (SCCT) 19th Annual Scientific Meeting, SCCT24, “At the heart of it,” to be held July 18-21, in Washington, DC. A Welcome Reception will close out the day in the exhibit hall from 6:00 p.m. - for all attendees. 3:00 p.m. . - 5:00 p.m.,
Publication date: Available online 26 April 2024 Source: The American Journal of Cardiology Author(s): Pedro Engel Gonzalez, Annika Hebbe, Yasin Hussain, Rohan Khera, Subhash Banerjee, Mary E Plomondon, Stephen W. Waldo, Steven E. Pfau, Jeptha P. Curtis, Samit M.
Circulation, Volume 150, Issue Suppl_1 , Page A4144277-A4144277, November 12, 2024. However, the long-term outcomes in patient with an intermediate stenosis received FFR have not yet been investigated comprehensively.Methods:We retrospective included 558 patients underwent both coronaryartery angiography (CAG) and FFR.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronaryartery inflammation and accurately predict cardiac events. fold higher risk for cardiac mortality and 5.5-fold
Circulation, Volume 150, Issue Suppl_1 , Page A4143220-A4143220, November 12, 2024. We evaluated patterns of evidence-based prescription of SGLT2i and GLP1RA over time and by race in US Veterans with T2D and coronaryarterydisease (CAD).Results:Of
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content